Strategic partnering to enable cell therapy commercialization: an ArsenalBio case study

Cell & Gene Therapy Insights 2022; 8(9), 925

DOI: 10.18609/cgti.2022.138

Published: 4 November 2022
Jenessa Smith

As emerging cell therapies move towards the commercialization phase, focus has been placed on establishing scalable and reproducible manufacturing processes and incorporating innovations to streamline cell therapy manufacturing. Strategic partnering between biotech and pharma companies can facilitate the challenging transition of moving cell therapies through the commercialization pipeline.